Different T lymphocyte populations, including CD4+, CD8+, and Treg, along with different neutrophil phenotypes (N1 or N2), may be responsible for the balance between pro-inflammatory and pro-immunogenic responses in the different breast cancer subtypes, and this may eventually influence clinical outcome. The gene discussed is CD4; the disease is breast cancer.